MPO and mastitis: Moreover, we found that the SRMT group had several increases in mastitis parameters, including MPO activity, TNF-α, and IL-1β levels, compared with the control and HRMT groups (Fig. 11N–P); however, zanamivir treatment alleviated these increases compared with those of the SRMT group (Fig. 11N–P).